in effect
This is an executive order (Executive Order 14200, signed February 5, 2025). It amends an earlier executive order from February 1, 2025, that imposed duties (tariffs) on certain goods from China connected to the synthetic opioid supply chain. It changes a single provision of that earlier order dealing with “de minimis” treatment.
It replaces subsection (g) of section 2 of the February 1 order with new text. Under the revised language, duty-free “de minimis” treatment (allowed under 19 U.S.C. 1321, the rule that lets eligible low-value shipments enter without paying duties) remains available for the covered articles for the time being. That duty-free treatment will end once the Secretary of Commerce notifies the President that adequate systems are in place to fully and quickly process and collect the tariff revenue owed on those articles. The order sets no calendar date; the cutoff is triggered by the Commerce Secretary’s notification. It also states it creates no new legal rights and is to be carried out consistent with applicable law and available funding.
Importers and shippers bringing the covered low-value goods from China into the United States are the parties directly affected. Until the Secretary of Commerce reports that collection systems are ready, those shipments can still enter duty-free under de minimis; after that notification, they become subject to the tariffs from the underlying order. The Secretary of Commerce effectively controls the timing of that switch.